S
Stoicheia
Nanotechnology company accelerating materials discovery by defining and expanding the materials genome
About Stoicheia
Stoicheia, which rebranded to Mattiq in January 2023, is a company focused on accelerating the discovery of new materials, particularly for the clean energy and chemical industries. Founded in 2021 by nanotechnology pioneer Chad A. Mirkin, the company originated from decades of research at Northwestern University's International Institute for Nanotechnology. The firm secured a $5 million seed funding round at its launch, with backers including notable figures from the tech and investment sectors.
The core of the company's business is its 'chemistry for climate' platform, which integrates proprietary artificial intelligence with high-throughput screening technology to revolutionize materials discovery. This approach allows for the rapid and systematic exploration of the materials genome. The company utilizes a unique lithography technique to create what it calls "Megalibraries"—chips containing over a million distinct nanostructures per square centimeter. These libraries enable millions of experiments to be conducted simultaneously, drastically reducing the time and cost associated with traditional serial-screening processes.
Mattiq serves industries such as petrochemicals, energy, transportation, and pharmaceuticals by identifying new materials with specific, desirable properties. A primary application of their technology is to find alternatives to scarce and expensive materials, like iridium, which is used in the production of green hydrogen. By developing commercially viable methods for producing e-chemicals and e-fuels, Mattiq aims to help industries decarbonize. The business model centers on leveraging its advanced materials discovery platform to develop and commercialize these novel materials, addressing critical bottlenecks in the transition to a net-zero economy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- Skokie, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 27.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Technology
- Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2022 | $9.2M | $37M | Undisclosed | ↗ |
| SEEDEquity / VC | Jan 2019 | $5M | $20M | Kairos Ventures | — |
Growth signals
Latest recorded traffic for Stoicheia is 120 monthly website visits, down 45.5% over the last three months. Stoicheia's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Kairos Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stoicheia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stoicheia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






